Search is Powered by Google
Cancer / Oncology News

The Forgotten Cancer - European Patient Group Formed

Main Category: Cancer / Oncology
Article Date: 16 Nov 2008 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

European advocacy and support groups working with patients who have some of the rarest cancers have agreed to form a collaborative association.

Sarcoma Patients EuroNet (SPAEN) will start work in January 2009 with the aim of extending information services, patient support and advocacy so that patients across the whole of Europe can benefit. Five leading patient groups in Germany, France and the UK are the founding members of SPAEN, and membership of the association is open to patient groups anywhere in Europe who work with sarcoma patients.

In many European countries sarcoma is a 'forgotten cancer'. There is little understanding in the healthcare system of the patient benefit that specialist treatment centres offer or of the better patient outcomes which come from doctors who regularly treat these rare cancers. Many patients get no access to information about their disease or their treatments, and without access to the internet knowledge of new treatments is hard to come by.

Sarcomas are very rare. They account for about 1% of all cancers diagnosed, but there are about 50 different sub-types, and these tumours can appear almost anywhere on or in the body. SPAEN will organise training to help patient groups understand sarcoma, and advise patients wishing to create new advocacy groups. The members will share their resources (leaflets, information, books etc) and develop new material for patients under the SPAEN banner.

SPAEN is being supported by the pan-European collaboration of sarcoma specialist researchers and doctors, Conticanet. The two associations will work together to ensure that information on clinical trials is widely promoted and accessible to patients. Through Conticanet it is also planned that patients will have an voice in future clinical trial development.

The founding members are:

Sarcoma UK - www.sarcoma-uk.org
GIST Support UK - www.gistsupportuk.com
Das Lebenshaus - www.daslebenshaus.org
SOS Desmoid - www.sos-desmoid.de
Ensemble Contre Le GIST - www.ensemblecontrelegist.org

The new association will be based in Bad Nauheim, Germany with its administration provided by Das Lebenshaus.

More information can be downloaded from www.sarcoma-uk.org/docs/spaen.pdf




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...